To overcome the myelosuppression after CAR-T therapy, Minagawa et al. designed selectively inducible Caspase-9-CAR-T-cells which could specifically lyse CD33+ AML cells in vitro, largely eliminating CAR-T-cells by suicide gene activation [40]. This evidence concerns the gene CD33 and acute myeloid leukemia.